[Ocular pulse amplitude and local carbonic anhydrase inhibition].
Ocular perfusion is increasingly being discussed in the pathogenesis of glaucoma. The present study was designed to investigate ocular pulse amplitude (OPA) in primary open-angle glaucoma (POAG) patients with elevated intraocular pressure (HTG) and non-glaucomatous controls (CTL) following topical application of the carbonic anhydrase inhibitor dorzolamide.


METHODS
OPA (Ocular Blood Flow System, OBF Labs UK) intraocular pressure (IOP), heart rate (HR), and systolic (BPsyst) and diastolic (BPdiast) bronchial artery pressures were measured before and 2 days after initiating treatment in 33 cataract patients with n = 14) and without (n = 19) POAG.


RESULTS
Following application of dorzolamide, IOP (mmHg) in drug-treated HTG and CTL eyes was highly significantly reduced (p < 0.001) and in vehicle-treated HTG and CTL eyes significantly reduced (p < 0.03) compared to respective baseline measurements. OPA (mmHg) in drug-treated HTG and CTL eyes was significantly increased (p < 0.05) and in vehicle-treated eyes in affected compared to respective baseline measurements. Systemic perfusion parameters were also unchanged.


CONCLUSIONS
Dorzolamide increased OPA in HTG and CTL eyes. An increase in OPA may improve the prognosis of HTG.
Schmidt
K G
KG
Universitäts-Augenklinik Giessen.
Dick
B
B
von Rückmann
A
A
Pillunat
L E
LE
D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects*; D002257:Carbonic Anhydrase Inhibitors / Q000008:administration & dosage*; D005123:Eye / Q000098:blood supply*; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy* / Q000209:etiology; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D011673:Pulsatile Flow / Q000187:drug effects*; D012039:Regional Blood Flow / Q000187:drug effects; D013449:Sulfonamides / Q000008:administration & dosage*; D013876:Thiophenes / Q000008:administration & dosage*
D002257:Carbonic Anhydrase Inhibitors; D009883:Ophthalmic Solutions; D013449:Sulfonamides; D013876:Thiophenes; C062765:dorzolamide